Pulse Biosciences, Inc. (PLSE) Cash Flow Statement

The persistent gap between net income and operating cash flow appears largely driven by significant stock-based compensation and other non-cash charges. Investors should monitor whether this divergence narrows as the company attempts to transition toward a more commercialized revenue model.

The lack of positive FCF margins suggests that the company is currently in a capital-intensive phase where cash consumption is decoupled from revenue growth. This trend warrants further investigation into how long the current cash position can sustain operations before additional dilutive financing becomes necessary.

The low absolute level of capital expenditure suggests that the company may be outsourcing key manufacturing processes or deferring significant infrastructure investment until clinical validation is achieved. This strategy appears to preserve cash in the short term but may create bottlenecks if the company successfully scales its commercial operations.

These fluctuations suggest that the company is likely managing inventory build-ups in anticipation of clinical milestones or regulatory approvals. Investors should monitor these shifts as they may indicate early-stage supply chain friction or challenges in converting inventory into realized cash flow.